
Listen instead
An 18-patient cohort with advanced dry age-related macular degeneration has provided the primary clinical foundation for a major capital expansion in the neurotech sector. Under the retina of these patients sits a wireless photovoltaic chip measuring two millimeters, designed to convert near-infrared light from specialized glasses into electrical signals. The technology, known as the PRIMA retinal implant system, represents an effort by Science Corporation to transition neural prosthetics from academic research into clinical practice.
Science Corporation announced a 400 million dollar Series D funding round, which the company states brings its total capital raised to more than 900 million dollars. According to reports from Bloomberg and TechCrunch, the transaction values Science Corporation at approximately 3.5 billion dollars. The company plans to use the capital to expand its commercial operations for the PRIMA system in Europe and to prepare for regulatory submission and market entry in the United States.
Clinical evidence and patient outcomes
The commercial strategy for the PRIMA system relies on clinical trial data tracking visual acuity over an extended period. In the PRIMAvera study, researchers monitored patients with geographic atrophy, an advanced stage of dry age-related macular degeneration that causes permanent loss of central vision.
According to data released by the company, the 18 patients who completed the 36-month assessment showed progressive improvements in visual performance. At the 12-month mark, patients could read an average of 24.5 additional letters on standard eye charts. By the 36-month assessment, that average increased to 29 additional letters. The company reported that 14 of the participants gained 15 or more letters of visual acuity, which represents a significant change in functional vision for individuals who previously could not read text.
These long-term findings have not yet appeared in a peer-reviewed scientific journal. For clinicians and regulatory bodies, peer-reviewed publication remains the standard for validating safety and efficacy data. Completing this step will be critical for the company to establish deep scientific consensus within the ophthalmic community.
Navigating the international regulatory landscape

Science Corporation is pursuing a dual-track strategy to commercialize the PRIMA system in international markets, navigating different regulatory frameworks in Europe and the United States.
In Europe, the system has secured a CE mark, certifying that it meets safety and performance standards for the European Economic Area. This certification allows the company to establish its initial commercial operations, refine surgeon training protocols, and build clinical referral networks in European markets.
For the United States market, Science Corporation is pursuing a distinct regulatory pathway. Rather than seeking standard premarket approval, the company is applying for Food and Drug Administration clearance through the Humanitarian Device Exemption pathway. This program is designed for medical devices that target rare conditions, allowing for regulatory clearance based on safety and probable benefit. This pathway bypasses the large-scale efficacy trials typically required for high-risk class three medical implants, potentially shortening the timeline to market.
Chief Executive Officer Max Hodak has stated that the company expects the PRIMA system to achieve U.S. market availability in the first half of 2027. However, this projected timeline remains subject to the speed and outcomes of the federal regulatory review process.
Commercial feasibility and scaling hurdles

The scale of the funding round highlights a growing investment interest in brain-computer interfaces and neural prosthetics. While media attention frequently centers on invasive cortical implants that require direct brain surgery, Science Corporation is demonstrating that sub-retinal implants can attract significant private capital.
However, the commercialization of implantable medical devices involves operational complexities that extend beyond securing regulatory clearance. The United States Humanitarian Device Exemption pathway, while offering a faster route to market, carries strict statutory restrictions. Devices approved under this program are generally subject to annual volume limits on the number of units that can be sold for profit. This restriction could limit initial revenue generation in the American market during the early years of launch.
Long-term commercial success will also depend on securing robust reimbursement policies from public and private health insurers. Without clear reimbursement codes, the high costs associated with the implant, the external hardware, and the surgical procedure will limit adoption to self-paying patients. Additionally, the company must establish structured training programs for ophthalmic surgeons, as the precise placement of a sub-retinal chip requires specialized surgical skills. Managing patient selection criteria will also be critical to ensure the device is implanted only in individuals who have the appropriate retinal architecture to benefit from the technology.
Source: Science Corporation

